nach oben

Erschienen in:

06.06.2020 | Original Research

Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer

verfasst von: Samantha A. Diamond-Rossi, Jacqueline Jonklaas, Roxanne E. Jensen, Charlene Kuo, Selma Stearns, Giuseppe Esposito, Bruce J. Davidson, George Luta, Gary Bloom, Kristi D. Graves

Erschienen in: Journal of Cancer Survivorship | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite having a generally favorable prognosis, differentiated thyroid cancer is known to have a significant, long-term impact on the quality of life of survivors. We wished to investigate short- and long-term effects among thyroid cancer survivors following radioactive iodine therapy.

Methods

We conducted eight focus groups (N = 47) to understand patients’ experiences of short- and long-term effects after radioactive iodine treatment and the impact these treatment-related side effects had on patients’ quality of life. We elicited responses regarding experiences with side effects following radioactive iodine treatment, particularly salivary, lacrimal, and nasal symptoms. We transcribed audiotapes and conducted qualitative analyses to identify codes and themes.

Results

We identified eight broad themes from the qualitative analyses. Themes reflecting physical symptoms included dry mouth, salivary gland dysfunction, altered taste, eye symptoms such as tearing or dryness, and epistaxis. Psychosocial themes included lack of knowledge and preparation for treatment, regret of treatment, and distress that thyroid cancer is labeled as a “good cancer.”

Conclusions

Thyroid cancer survivors reported a wide range of radioactive iodine treatment-related effects and psychosocial concerns that appear to reduce quality of life. The psychosocial concerns reported by participants underscore the significant unmet information and support needs prior to and following RAI treatment among individuals diagnosed with thyroid cancer.

Implications for Cancer Survivors

Future research is needed to help both patients and physicians understand the effect of radioactive iodine on quality of life, and to better assess the benefits versus the risks of radioactive iodine therapy.

Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–48.PubMed

Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52(3):784–95.PubMed

Chow SM, Yau S, Kwan CK, Poon PC, Law SC. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006;13(4):1159–72.PubMed

Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–80 quiz 80.PubMed

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.PubMedPubMedCentral

Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–42.PubMed

Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019;29(1):7–26.PubMed

American Thyroid Association Taskforce On Radioiodine S, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335–46.

Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid. 2013;23(6):683–94.PubMed

10.

Sacks W, Wong RM, Bresee C, Braunstein GD. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid. 2015;25(4):377–85.PubMed

11.

Park KW, Wu JX, Du L, Leung AM, Yeh MW, Livhits MJ. Decreasing use of radioactive iodine for low-risk thyroid cancer in California, 1999 to 2015. J Clin Endocrinol Metab. 2018;103(3):1095–101.PubMed

12.

Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid. 2004;14(2):133–40.PubMed

13.

Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med. 1996;21(10):780–2.PubMed

14.

Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27(11):767–71.PubMed

15.

Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42(5):738–43.PubMed

16.

Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys. 1996;35(3):535–40.PubMed

17.

Hoelzer S, Steiner D, Bauer R, Reiners C, Farahati J, Hundahl SA, et al. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med. 2000;27(10):1465–72.PubMed

18.

Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46(2):261–6.PubMed

19.

Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med. 1984;25(7):755–8.PubMed

20.

Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009;50(10):1605–10.PubMed

21.

Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J HK Coll Radiol. 2005;8:127–35.

22.

Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(12):5817–20.PubMed

23.

Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging. 2002;29(11):1428–32.PubMed

24.

Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27(10):1519–27.PubMed

25.

Jonklaas J. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction. Thyroid. 2014;24(12):1806–14.PubMedPubMedCentral

26.

Goswami S, Peipert BJ, Mongelli MN, Kurumety SK, Helenowski IB, Yount SE, et al. Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. Surgery. 2019.

27.

Mols F, Schoormans D, Smit JWA, Netea-Maier RT, Links TP, van der Graaf WTA, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry. Head Neck. 2018;40(10):2235–45.PubMed

28.

Wang T, Jiang M, Ren Y, Liu Q, Zhao G, Cao C, et al. Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. Thyroid. 2018;28(8):1013–23.PubMed

29.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2018;32(4):952–9.PubMed

30.

Sawka AM, Naeem A, Jones J, Lowe J, Segal P, Goguen J, et al. Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review. Endocrinol Metab Clin North Am. 2014;43(2):475–94.PubMed

31.

Rogers SN, Mepani V, Jackson S, Lowe D. Health-related quality of life, fear of recurrence, and emotional distress in patients treated for thyroid cancer. Br J Oral Maxillofac Surg. 2017;55(7):666–73.PubMed

32.

Lee JI, Kim SH, Tan AH, Kim HK, Jang HW, Hur KY, et al. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes. 2010;8:101.PubMedPubMedCentral

33.

Duan H, Gamper E, Becherer A, Hoffmann M. Quality of life aspects in the management of thyroid cancer. Oral Oncol. 2015;51(6):S1–5.PubMed

34.

Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S, et al. The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. PLoS One. 2009;4(1):e4191.PubMedPubMedCentral

35.

Aschebrook-Kilfoy B, Ferguson BA, Angelos P, Kaplan EL, Grogan RH, Gibbons RD. development of the ThyCAT: a clinically useful computerized adaptive test to assess quality of life in thyroid cancer survivors. Surgery. 2018;163(1):137–42.PubMed

36.

James BC, Aschebrook-Kilfoy B, White MG, Applewhite MK, Kaplan SP, Angelos P, et al. Quality of life in thyroid cancer-assessment of physician perceptions. J Surg Res. 2018;226:94–9.PubMed

37.

Easley J, Miedema B, Robinson L. It's the "good" cancer, so who cares? Perceived lack of support among young thyroid cancer survivors. Oncol Nurs Forum. 2013;40(6):596–600.PubMed

38.

Randle RW, Bushman NM, Orne J, Balentine CJ, Wendt E, Saucke M, et al. Papillary Thyroid cancer: the good and bad of the "good cancer". Thyroid. 2017;27(7):902–7.PubMedPubMedCentral

39.

Goldfarb M, Casillas J. Unmet information and support needs in newly diagnosed thyroid cancer: comparison of adolescents/young adults (AYA) and older patients. J Cancer Surviv. 2014;8(3):394–401.PubMed

40.

Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101. https://doi.org/10.1191/1478088706qp063oa.CrossRef

41.

Sandelowski M. Combining qualitative and quantitative sampling, data collection, and analysis techniques in mixed-method studies. Res Nurs Health. 2000;23(3):246–55.PubMed

42.

Miles MB, Huberman M. Qualitative Data Analysis. Thousand Oaks: SAGE Publications; 1994.

43.

Choi Y, Lee JH, Kim YH, Lee YS, Chang HS, Park CS, et al. Impact of postthyroidectomy scar on the quality of life of thyroid cancer patients. Ann Dermatol. 2014;26(6):693–9.PubMedPubMedCentral

44.

Nygaard B, Bastholt L, Bennedbaek FN, Klausen TW, Bentzen J. A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. Eur Thyroid J. 2013;2(3):195–202.PubMedPubMedCentral

45.

Saeed O, Bernstein LJ, Fazelzad R, Samuels M, Burmeister LA, Thabane L, et al. Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2019;13(2):231–43.PubMed

46.

Morley S, Goldfarb M. Support needs and survivorship concerns of thyroid cancer patients. Thyroid. 2015;25(6):649–56.PubMed

47.

Sawka AM, Straus S, Gafni A, Brierley JD, Tsang RW, Rotstein L, et al. How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation? Clin Endocrinol (Oxf). 2011;74(4):419–23.PubMedPubMedCentral

48.

Hyun YG, Alhashemi A, Fazelzad R, Goldberg AS, Goldstein DP, Sawka AM. A Systematic Review of Unmet Information and Psychosocial Support Needs of Adults Diagnosed with Thyroid Cancer. Thyroid. 2016;26(9):1239–50.PubMed

49.

Husson O, Mols F, Oranje WA, Haak HR, Nieuwlaat WA, Netea-Maier RT, et al. Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: results of the PROFILES registry. Psychooncology. 2014;23(8):946–52.PubMed

50.

Wallner LP, Reyes-Gastelum D, Hamilton AS, Ward KC, Hawley ST, Haymart MR. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer. J Clin Oncol. 2019:JCO1802228.

51.

Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, et al. Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv. 2018;12(5):702–11.PubMedPubMedCentral

52.

Yaish I, Azem F, Gutfeld O, Silman Z, Serebro M, Sharon O, et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study. Thyroid. 2018;28(4):522–7.PubMed

53.

Bourcigaux N, Rubino C, Berthaud I, Toubert ME, Donadille B, Leenhardt L, et al. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. Hum Reprod. 2018.

54.

Davies L, Hendrickson CD, Hanson GS. Experience of US Patients who self-identify as having an overdiagnosed thyroid cancer: a qualitative analysis. JAMA Otolaryngol Head Neck Surg. 2017;143(7):663–9.PubMedPubMedCentral

55.

Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid. 2013;23(5):609–16.PubMedPubMedCentral

56.

Jonklaas J, Wang H, Esposito G. Salivary function after radioiodine therapy: poor correlation between symptoms and salivary scintigraphy. Front Endocrinol (Lausanne). 2015;6:100.

Titel: Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer
verfasst von: Samantha A. Diamond-Rossi
Jacqueline Jonklaas
Roxanne E. Jensen
Charlene Kuo
Selma Stearns
Giuseppe Esposito
Bruce J. Davidson
George Luta
Gary Bloom
Kristi D. Graves
Publikationsdatum: 06.06.2020
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 6/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00897-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Can the provision of sexual healthcare for oncology patients be improved? A literature review of educational interventions for healthcare professionals

A structural equation modeling approach to understanding pathways linking survivorship care plans to survivor-level outcomes

Physical functional limitations and psychological distress in people with and without colorectal cancer: findings from a large Australian study

Feasibility of eccentric overloading and neuromuscular electrical stimulation to improve muscle strength and muscle mass after treatment for head and neck cancer

The use of survivorship care plans by female racial and ethnic minority breast cancer survivors: a systematic review

Identifying patients’ priorities for quality survivorship: conceptualizing a patient-centered approach to survivorship care

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie